| Species |
Cynomolgus |
| Protein Construction |
EPHB2 (Val19-Pro542)
Accession # A0A7N9CQH5 |
His |
| N-term |
C-term |
|
| Purity |
> 95% as determined by BisTris PAGE
> 95% as determined by HPLC |
| Endotoxin Level |
Less than 1EU per μg by the LAL method. |
| Biological Activity |
Measured by its binding ability in a functional ELISA. Immobilized EPHB2, His, Cynomolgus at 1μg/ml (100μl/Well) on the plate can bind AntiEPHB2 Antibody, hFc Tag. Test result was comparable to standard batch. |
| Expression System |
HEK293 |
| Theoretical Molecular Weight |
59.09 kDa |
| Apparent Molecular Weight |
Due to glycosylation, the protein migrates to 65-75 kDa based on Bis-Tris PAGE result. |
| Formulation |
Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). |
| Reconstitution |
Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. |
| Storage & Stability |
Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles. |
| Target Background |
EphB2, a receptor tyrosine kinase for ephrin ligands, is overexpressed in various cancers and plays an important role in tumor progression. EPHB2 promotes endothelial-mesenchymal transition (EMT) and elicits associated pathologic characteristics of glioblastoma multiforme (GBM) such as invasion and migration. EPHB2 is epigenetically overexpressed in hypoxia, a condition highly prevalent in malignancy. Furthermore, HIF-2α is required for EPHB2 stabilization by hypoxia. |
| Synonyms |
DRT; ERK; HEK5; TYRO5; CAPB; EK5; EPHT3; PCBC; Cek5; EphB2; EPHT3MGC87492; Nuk; Qek2; Sek3 |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
